BOEHRINGER INGELHEIM PHARMA GMBH &CO KG

Their core work

Boehringer Ingelheim is one of the world's largest research-driven pharmaceutical companies, headquartered in Ingelheim, Germany. Within H2020, their pharma division contributes deep drug development and safety pharmacology expertise to academic training networks, particularly through MSCA programmes. They provide industrial PhD placements and real-world pharmaceutical R&D environments for early-stage researchers working on disease modelling, cardiovascular safety, neuroinflammation, and organ-on-a-chip technologies. Their role is that of an industry host bringing commercial drug development context to multi-partner research training consortia.

What they specialise in

How they've shifted over time

In their earlier H2020 period (2015–2018), Boehringer Ingelheim engaged in biomanufacturing (CHO cell engineering) and data-driven chemistry, reflecting classic pharma R&D infrastructure concerns. From 2018 onward, their focus shifted decisively toward disease mechanism research — organ-on-a-chip platforms, neuroinflammation, cardiovascular thrombosis, and safety pharmacology — indicating a strategic move from process-oriented to translational and preclinical research partnerships. This evolution mirrors the broader pharmaceutical industry trend toward advanced in-vitro models and reduced animal testing.

Boehringer Ingelheim is increasingly investing in advanced preclinical platforms (organ-on-a-chip, iPSC-based models) and cardiovascular/neurological safety assessment — expect continued interest in alternatives to animal testing and translational disease modelling.

How they like to work

Boehringer Ingelheim never coordinates H2020 projects — they participate exclusively as a partner or third party in MSCA training networks, providing industrial secondment placements for PhD researchers. With 98 unique consortium partners across 21 countries, they connect broadly but selectively, joining well-established academic consortia rather than building their own. This is typical of large pharma companies that use EU-funded training networks to access early-stage talent and academic innovation without taking on coordination overhead.

They have collaborated with 98 unique partners across 21 countries, giving them a wide European academic network despite their modest project count. Their partnerships span universities, research institutes, and other industrial players involved in MSCA Innovative Training Networks.

What sets them apart

As a top-20 global pharmaceutical company, Boehringer Ingelheim brings something most H2020 partners cannot: direct access to industrial drug development pipelines and regulatory-grade safety pharmacology expertise. Their consistent involvement in MSCA training networks signals genuine commitment to training the next generation of pharmaceutical scientists, not just token industry participation. For academic groups seeking an industrial partner with real preclinical testing infrastructure and therapeutic area depth in cardiovascular and neurological diseases, they are a credible and experienced choice.

Highlights from their portfolio

• INSPIRE
  Directly targets a major pharma pain point — improving cardiovascular safety assessment to reduce adverse drug reactions, with clear regulatory and commercial relevance.
• EUROoC
  Positions Boehringer Ingelheim at the forefront of organ-on-a-chip technology adoption in pharma, a field expected to transform preclinical drug testing.
• BIGCHEM
  Their largest single EC contribution (EUR 463,820), applying big data approaches to chemistry — an early signal of their interest in computational drug discovery.